AstraZeneca calls off two late-stage potassium drug trials, Top Health News | Latest Healthcare Sector & Healthcare Industry news, Information and Updates: ET HealthWorld : ETHealthworld.com

“The decision to discontinue the trials is not due to safety concerns and the positive benefit-risk of Lokelma does not change in the approved indication,” AstraZeneca said in a statement on Friday., “The decision to discontinue the trials is not due to safety concerns and the positive benefit-risk of Lokelma does not change in the approved indication,” AstraZeneca said in a statement on Friday., , Read More